前caplacizumab时代血栓性血小板减少性紫癜患者脑损伤模式
法国单中心前瞻性队列纳入130例新诊断TTP患者,108例(83%)有神经系统体征,最常见头痛(51%)、肢体无力/感觉异常/失语(49%)、认知障碍(34%)。层次聚类分析识别出三个集群:集群1年轻、头痛为主;集群2共济失调/小脑综合征和头晕为主;集群3谵妄、意识模糊和癫痫为主,且急性肾损伤比例更高(77% vs 68% vs 32%)。中位随访34个月,93%存活,89%完全神经认知恢复(GOS 5分),集群1在3月、6月、1年时完全恢复率均显著高于集群2和3。
要点
- 入院神经系统查体可将TTP患者分为三集群:集群1以头痛为主(75%),集群2以小脑综合征/共济失调(77%)和头晕(50%)为主,集群3以谵妄(36%)、意识模糊(58%)和癫痫(36%)为主。
- 集群3患者急性肾损伤比例最高(77%),集群2为68%,集群1为32%(p<0.0001),提示脑损伤模式与全身器官受累相关。
- 集群1患者3个月完全神经认知恢复(GOS 5分)比例98%,显著高于集群2(65%)和集群3(60%)(p<0.0001)。
- 中位随访34个月,93%患者存活,89%达GOS 5分;但集群2和3的1年完全恢复率仍仅79%和57%。
- 三集群在其它生物学指标和脑影像学上无差异,提示早期临床神经查体即可分层,无需等待影像。
适用人群与场景
- 法国单中心ICU连续纳入的新诊断血栓性血小板减少性紫癜成人患者(年龄43 [30-52]岁,73%女性)。
诊断标准与关键阈值
- 神经认知恢复采用Glasgow Outcome Scale评估(范围1-5分,1分代表死亡,5分代表无或极轻微神经功能缺损)。
- 原文未提及TTP诊断标准的具体条目或阈值。
处置流程与药物剂量
- 原文未提及具体治疗药物、剂量或处置流程。
红旗征与不能漏的情况
- 入院时出现谵妄、意识模糊或癫痫(集群3表现)提示神经认知恢复较差,1年完全恢复率仅57%。
- 入院时出现共济失调/小脑综合征或头晕(集群2表现)同样提示恢复较差,1年完全恢复率79%。
- 集群3患者急性肾损伤比例高达77%,需警惕多器官受累。
研究设计与关键结果
- 研究类型:前瞻性法国队列,单中心ICU,样本量130例新诊断TTP患者,其中108例(83%)有神经系统体征。
- 主要发现:层次聚类分析识别三个集群,集群1年轻(37 [27-48]岁)且头痛为主(75%);集群2共济失调/小脑综合征(77%)和头晕(50%)为主;集群3谵妄(36%)、意识模糊(58%)、癫痫(36%)为主。
- 急性肾损伤在集群1、2、3中分别为32%、68%、77%(p<0.0001);三集群其它生物学指标和脑影像学无差异。
- 随访结果:中位随访34个月(12-71月),100例(93%)存活,89例(89%)达GOS 5分。
- 集群1 vs 集群2 vs 集群3的GOS 5分比例:3个月为98% vs 65% vs 60%(p<0.0001);6个月为100% vs 68% vs 69%(p<0.0001);1年为100% vs 79% vs 57%(p<0.0001)。
证据类型、等级与局限
- 证据类型:前瞻性单中心队列研究。
- 局限:单中心、样本量130例、观察性设计,原文未提及盲法或混杂控制;聚类分析为探索性,需外部验证。
对床旁实践的改变
- 对新诊断TTP患者,入院时详细神经系统查体(头痛、共济失调、头晕、谵妄、意识模糊、癫痫)可帮助早期识别神经恢复较差的集群(集群2和3),从而调整监护强度和家属沟通预期。
- 集群3患者需同时关注急性肾损伤(发生率77%),加强肾功能监测。
- 原文未提及基于集群分层的特异性治疗调整,故不能据此改变TTP治疗方案。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To describe short- and long-term neurologic prognosis of patients with thrombotic thrombocytopenic purpura and to identify clusters associated with evolution.
DESIGN: Prospective French cohort.
SETTING: ICU in a reference center.
PATIENTS: All consecutive patients with newly diagnosed thrombocytopenic purpura.
INTERVENTION: Comprehensive clinical, biological, and radiological evaluation at admission. Neurocognitive recovery was assessed using Glasgow Outcome Scale (range 1-5, with 1 representing death and 5 representing no or minimal neurologic deficit).
MEASUREMENTS AND MAIN RESULTS: Among the 130 newly diagnosed patients with thrombocytopenic purpura, 108 (83%; age 43 [30-52]; 73% women) presented with neurologic signs, including headaches (51%), limb weakness, paresthesia, and/or aphasia (49%), pyramidal syndrome (30%), decreased consciousness (20%), seizure (19%), cognitive impairment (34%), cerebellar syndrome (18%), and visual symptoms (20%). A hierarchical cluster analysis identified three distinct groups of patients. Cluster 1 included younger patients (37 [27-48], 41 [32-52], and 48 [35-54], in clusters 1, 2 and 3, respectively; p = 0.045), with a predominance of headaches (75%, 27%, and 36%; p < 0.0001). Cluster 2 patients had ataxic gait and cerebellar syndrome (77%, 0%, and 0%; p < 0.0001) and dizziness (50%, 0%, and 0%; p < 0.0001). Cluster 3 included patients with delirium (36%, 0%, and 9%; p < 0.0001), obtundation (58%, 0%, and 24%; p < 0.0001), and seizure (36%, 0%, and 14%; p < 0.0001). Acute kidney injury was 32%, 68%, and 77%, in clusters 1, 2, and 3, respectively (p < 0.0001). The three clusters did not differ for other biological or brain imaging. After a median follow-up of 34 months (12-71 mo), 100 patients (93%) were alive with full neurocognitive recovery (i.e., Glasgow Outcome Scale score 5) in 89 patients (89%). Patients from cluster 1 more frequently exhibited full recovery (Glasgow Outcome Scale score of 5) compared with clusters 2 and 3, (44 [98%], 13 [65%], and 21 [60%] at 3 mo; p < 0.0001), (44 [100%], 15 [68%], and 23 [69%] at 6 mo; p < 0.0001), and (40 [100%], 15 [79%], and 20 [57%] at 1 yr; p < 0.0001).
CONCLUSIONS: Initial clinical neurologic evaluation in thrombocytopenic purpura patients distinguishes three groups of patients with different clinical and functional outcomes.
参考来源
- Mirouse A, Legriel S, Dumas G, et al. Pattern of Brain Injury in Patients With Thrombotic Thrombocytopenic Purpura in the Precaplacizumab Era. Crit Care Med. 2021. PMID: 34166282. doi:10.1097/CCM.0000000000005164
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。